In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Eli Lilly (NYSE:LLY) shares dropped on Thursday after lowering its full-year outlook amid a decision by CVS Health (NYSE:CVS) ...

STAT editors and reporters review the widespread impact of grant cuts, layoffs and policy changes — and also discuss recent ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

An Eli Lilly spokesperson told Pharmaceutical Technology: “[The telehealth companies] are deceptively marketing knockoff ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Before Wednesday's lawsuits, Lilly had sued over a dozen pharmacies, medical spas and wellness centers for selling compounds of tirzepatide. American Airlines sues JetBlue after partnership fails ...